More highlights from European Cancer Congress from Boehringer and Roche

30 September 2013

More results have been presented at the European Cancer Congress (ECCO) in Amsterdam, Netherlands from companies including Swiss drug major Roche (ROG: SIX) and family-owned Boehringer Ingelheim of Germany.

Smokers could benefit from lung cancer antibody

Roche presented new results from a trial of an investigational antibody that helps the immune system to recognize and attack cancer cells which have shown encouraging responses in patients who are smokers or former smokers. The data is from 85 patients with non-small cell lung cancer in a large, Phase I clinical trial of experimental drug MPDL3280A (also known as anti-PDL1).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK